Fusion Pharmaceuticals Inc (FUSN) Stock
FUSN is no longer traded. Fusion Pharmaceuticals Inc was acquired by AstraZeneca (AZN) on June 3, 2024.
Each FUSN share was exchanged for $21.00 in cash plus a contingent value right of up to $3.00. Prices on this page are historical; the last trade was June 3, 2024 at $21.55.
See AstraZeneca (AZN) stock →Fusion Pharmaceuticals Inc stock price history
FUSN final trading statistics
- Final close
- $21.55
- Final trading day
- Jun 3, 2024
- Market cap at delisting
- $1.83B
- Shares outstanding
- 85.06M
- Final 52-week range
- $2.31 – $21.60
- Avg. volume (final 3 mo.)
- 1,966,047
- All-time high (split-adj.)
- $21.55 · Jun 2024
- All-time low (split-adj.)
- $1.98 · Nov 2022
- Return since IPO
- +26.8%
- Beta
- -0.69
- Book value / share
- $2.85
- Price / book
- 7.56
Fusion Pharmaceuticals Inc annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $2.07M | -$94.9M | -$1.47 |
| FY2022 | $1.46M | -$87.6M | -$2.00 |
| FY2021 | $1.44M | -$81.0M | -$1.90 |
| FY2020 | $521.0K | -$78.3M | -$19.76 |
| FY2019 | $0.00 | -$16.2M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada. As of June 4, 2024, Fusion Pharmaceuticals Inc. operates as a subsidiary of AstraZeneca AB.
Fusion Pharmaceuticals Inc stock FAQ
What happened to Fusion Pharmaceuticals Inc stock?
Fusion Pharmaceuticals Inc was acquired by AstraZeneca (AZN) on June 3, 2024. Shareholders received $21.00 in cash plus a contingent value right of up to $3.00 for each share. FUSN stock stopped trading on the Nasdaq, with a final close of $21.55 on June 3, 2024.
What did Fusion Pharmaceuticals Inc shareholders receive?
Each FUSN share was converted into $21.00 in cash plus a contingent value right of up to $3.00. The deal was valued at up to about $2.4 billion.
Is FUSN stock still trading?
No. FUSN was delisted from the Nasdaq on June 3, 2024 and no longer trades on a U.S. exchange.
What was the last price of FUSN stock?
FUSN closed at $21.55 on its final trading day, June 3, 2024, for a market value of about $1.83B.
What were Fusion Pharmaceuticals Inc's revenue and earnings in its last full fiscal year?
Fusion Pharmaceuticals Inc reported revenue of $2.07M and net income of -$94.9M in fiscal 2023, its last full year as a public company.
When did Fusion Pharmaceuticals Inc go public?
Fusion Pharmaceuticals Inc stock began trading on March 14, 2016.